Top-News

Inventiva Aktie News

Aktie
WKN:  A2DLV9 ISIN:  FR0013233012 US-Symbol:  IVEVF Branche:  Biotechnologie Land:  Frankreich
3,485 €
-0,04 €
-1,13%
05.12.25
Depot/Watchlist
Marktkapitalisierung *
294,77 Mio. €
Streubesitz
25,05%
KGV
-0,80
Index-Zuordnung
-

Inventiva News

10.06.25 - GlobeNewswire
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
27.05.25 - GlobeNewswire
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
23.05.25 - GlobeNewswire
Inventiva reports 2025 First Quarter Financial Information¹
Cash and cash equivalents at €67.9 million Daix (France),  New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a ...
23.05.25 - GlobeNewswire
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
Daix (France), New York City (New York, United States), May 23, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
22.05.25 - GlobeNewswire
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
Daix, May 22, 2025
05.05.25 - GlobeNewswire
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City ...
30.04.25 - GlobeNewswire
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...
30.04.25 - GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
Article R. 22-10-23 of the French Commercial Code
24.04.25 - GlobeNewswire
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
15.04.25 - GlobeNewswire
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Daix (France),  New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
01.04.25 - GlobeNewswire
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of ...
26.03.25 - GlobeNewswire
Inventiva reports its 2024 full year results and provides a business update
Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed ...
19.03.25 - GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Daix (France), New York City (New York, United States), March 19, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
26.02.25 - GlobeNewswire
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-​fibrotic PH Lanifibranor was observed to decrease ...
20.02.25 - GlobeNewswire
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 study Positive results could support the initiation of a pivotal ...
10.02.25 - GlobeNewswire
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed ...
01.02.25 - Börse-Global
Inventiva Aktie: Glänzende Performance!
Die französische Biotechnologiefirma Inventiva verzeichnete im Januar 2025 eine erfreuliche Entwicklung an den Börsen. Der Aktienkurs des Unternehmens konnte im ...
29.01.25 - GlobeNewswire
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
As previously reported 1 , the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton ...
25.01.25 - Boersia.de
Inventiva Aktie: Ein inspirierendes Jahr!
Die französische Biotechnologie-​Firma Inventiva steht heute im Rampenlicht der European Association for the Study of the Liver Steatotic Liver Disease Conference. Das ...
24.01.25 - GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »